Discovery of 225Ac-ETN029: A Peptide-based Radioligand Therapy for the Treatment of DLL3-expressing Solid Tumors

Name: Discovery of 225Ac-ETN029: A Peptide-based Radioligand Therapy for the Treatment of DLL3-expressing Solid Tumors
Start: 2027-04-28T17:15
End: 2027-04-28T17:45
Location: Hynes Convention Center

Tides 2027 · 28 April 2027 · 17:15–17:45

Discovery of 225Ac-ETN029: A Peptide-based Radioligand Therapy for the Treatment of DLL3-expressing Solid Tumors was a session at Tides 2027 on 28 April 2027 in Boston.